Company: BFRG
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023496
Chunk: 8

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 8
---
 stages of the development process. Artificial
intelligence and machine learning have emerged as a digital solution to help address this problem.

The
Company uses AI/ML to advance medicines for both internal and external projects. Currently, most AI/ML platforms still fall short in
their ability to synthesize disparate, high-dimensional data for actionable insight. The Company’s analytical platform is composed
of an ensemble of state-of-the-art machine learning and artificial intelligence models. The Company’s core platform technology,
bfLEAP™, is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (“JHU-APL”),
which the Company believes is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians
by providing a more precise, multi-dimensional understanding of their data. The Company is deploying its analytical platform, including
bfLEAP™, for use in several critical stages of development of internal programs and through strategic partnerships and collaborations
with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing
failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need.

The
proprietary analytical platform utilizes both supervised and unsupervised machine learning. As such, it can reveal real and meaningful
connections in the data without the need for a priori hypothesis. Algorithms used in the platform are designed to handle highly
imbalanced data sets and successfully identify combinations of factors that are associated with outcomes of interest. The Company’s
platform leverages models that use both correlative and causative machine learning and artificial intelligence approaches which provide
a comprehensive approach to predictive analysis that is expected to lead to meaningful insights including the molecular drivers of disease.
In this regard, with the Company’s access to proprietary data sets such as its strategic data and commercialization agreements
with the Lieber Institute for Brain Development (“LIBD”), the Company continues its internal efforts related to target discovery.

The
Company’s goal is to improve the odds of success at all stages of pre-clinical and clinical development for in-house programs and
for its strategic partners, collaborators, and customers. The Company’s business model includes enabling the success of ongoing
clinical trials and rescuing late stage failed drugs (i.e., Phase II or Phase III clinical trial failures) by bringing them in-house
for development prior to eventual divestiture; although, the Company also considers entering collaborations for earlier stage drugs.
The Company pursues its drug asset enhancement business by leveraging the